News
Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and ...
Novo Nordisk A/S’s best-sellers Ozempic and Wegovy transformed the firm into a global pharmaceutical giant. But four years ...
The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.
1d
Novo Nordisk stock crashes after company cuts sales, profit outlook on weight-loss drug competition
Danish drugmaker Novo Nordisk's stock was down nearly 20% in premarket trading Tuesday morning after the company cut its ...
Novo Nordisk said it expects weaker sales growth of its popular weight-loss drug Wegovy due to competition from copycat drugs ...
Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the ...
Novo Nordisk lowers 2025 guidance as Wegovy and Ozempic face slower U.S. uptake, competition, and continued compounded GLP-1 sales.
The pharmaceutical giant said multiple entities were still marketing and selling unbranded versions of its drug despite U.S.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback